Understanding the mechanisms underlying progression in multiple sclerosis (MS) and identifying appropriate therapeutic targets is a key challenge facing the MS community. This challenge has been championed internationally by organizations such as the Progressive MS Alliance, which has raised the profile of progressive MS and identified the key obstacles to treatment. This review will outline the considerable progress against these challenges.
INTRODUCTION
The challenge of finding treatments for and improving the management of progressive multiple sclerosis (MS) subsumes a number of fundamental issues, outlined in a publication from the International Progressive Multiple Sclerosis Alliance [1] . They include: (i) understanding the mechanisms underlying progression and identifying potential targets, (ii) appropriate trial design and outcome measures, and (iii) improving symptomatic treatment and rehabilitation.
The recent exploration of the MS phenotype and, in particular, comparison of the two progressive forms of MS has been helpful in that it acknowledges the consensus that while there are some differences between those that are progressive from onset (primary progressive) and those that develop progression after a period of relapses and remissions (secondary progressive), these differences are relative rather than absolute. This is not to dismiss the primary progressive phenotype which is considered by many to be the ideal model with which to study progression. An interesting study by Kantarci et al. [2 && ] followed a cohort of 453 study participants with so-called radiologically isolated syndromes (RIS), studied in 22 clinical sites. During a 15-year followup, 128 patients evolved to symptomatic MS and 15 of those developed primary progressive multiple sclerosis (PPMS) with a median time to conversion of 3.5 years, demonstrating that study participants with RIS evolve to PPMS in the same frequency as would be expected in general MS populations. The strongest predictors of evolution of PPMS included male gender, more advanced age, and the initial presence of asymptomatic spinal cord lesions. This frequency is, however, challenged by a recent Scandinavian study which suggests that the incidence of PPMS is reducing, falling from 19.2 to 2.2% over 30 years, a finding which needs verification in other populations [3] . The clinical definition of secondary progressive MS has also been quite challenging as it is invariably done retrospectively and tends to be further delayed because of impact on therapeutic options. The MSBase cohort study group worked through a bewildering number of options before reaching a definition which included the absence of a relapse, confirmed at 3 months, a score on the Expanded Disability Status Scale greater or equal to 4 and a pyramidal score greater or equal to 2 [4 && ].
MECHANISMS UNDERPINNING PROGRESSION
The fundamental issue in identifying treatments for progressive MS is a better understanding of the pathological mechanisms underlying progression, without which targets which are critical to that process cannot be identified with certainty [5] . This was the focus of a workshop which combined basic neuroscientists and clinicians which emphasized the urgent need to identify new therapeutic targets [6] . Although the role of some players such as microglia, mitochondria, and the innate immune system has been emphasized recently, the precise part they play is yet to be confirmed. A recent review explored potential mechanisms leading to secondary progression discussing a range of mechanisms, including aging, cumulative inflammatory injury exhausting resources, and distinct intrinsic mechanisms [7] . An intriguing study utilizing induced pluripotent stem cells, has suggested a defect in myelin injury response in PPMS, which could help explain the nature of progression [8] . More recently, an interesting study has highlighted the potential role of the kynurenine pathway in the development of progression, possibly through interaction with quinolinic acid produced by activated microglia and implicated in excitotoxic neurodegeneration [9] .
In addition, several studies have attempted to clarify the pathological processes underpinning MS which have direct implications for progression. The first describes a simplified classification of lesions [10] and the second provides a description of the topography of demyelination and neurodegeneration in MS and outlines two different patterns of neurodegeneration relating to oxidative injury and retrograde neurodegeneration [11] .
Mechanisms underlying progression can also be studied utilizing MRI. A recent study has explored the temporal relationship between white and grey matter damage in early PPMS by applying both conventional and magnetization transfer imaging to specific cortical areas and their connected tracts [12] . Results suggested that in the main, cortical damage is a sequelae of normal-appearing white matter pathology which in turn is determined by abnormalities within white matter lesions.
TRIAL DESIGN AND OUTCOMES
Moving from mechanisms, the next major challenge is around the practicalities of clinical trials and particularly the optimal trial design to evaluate an effect on progression and the ideal outcome measure to incorporate into such a trial, both at Phase II and Phase III level. Outcomes should include a clinical measure and a biomarker reflecting the underlying pathology and both pose challenges in progressive MS. Clinical evaluation continues to depend on the less than satisfactory Expanded Disability Status Scale. Biomarkers fall heavily toward MRI though work continues on cerebrospinal fluid markers, notably neurofilaments, and a recent study has suggested that they may have a predictive role in the development of atrophy in progressive MS [13] . Atrophy is the favoured imaging measure and has been used in a number of recent studies including the Phase II trial of simvastatin in progressive MS [14] . Efforts are tending to focus on regional atrophy, particularly deep grey matter and also on the spinal cord which may be particularly sensitive in trials of PPMS. Finally, biomarkers reflecting abnormalities of the visual pathway are becoming more prominent, most notably optical coherence tomography, a noninvasive technique which provides high-resolution quantification of the retinal nerve fibre layer, and directly reflects axonal integrity of the optic nerves and correlates with clinical disability [15 && ].
CLINICAL TRIALS IN PROGRESSIVE MULTIPLE SCLEROSIS
The last year has seen the publication of a number of clinical trials in progressive MS and while some have
KEY POINTS
Developing effective treatments for progressive MS is one of the key challenges for the MS community.
Understanding the mechanisms underpinning progression is fundamental to the identification of drugable targets.
Progress is being made in the development of appropriate trial design and outcome measure relevant to progression.
We now have the first effective treatment for primary progressive MS.
Increased focus on modifiable risk factors, symptom management, rehabilitation, and comorbidities will improve health-related quality of life for people with progressive MS.
been disappointingly negative, most recently we have seen a positive trial in PPMS. The trial of fingolimod, an oral sphingosine 1-phosphate modulator receptor, which was thought might have neuroprotective effects, was carried out in primary progressive MS, following the successful trial in the relapsing-remitting cohort [16] . A 3-year study of 970 patients utilizing a novel primary outcome which was a composite of the Expanded Disability Status Scale (EDSS), 25-foot timed walk test and the nine-hole peg test. The trial showed no difference between the treatment and placebo arms on any of the outcomes measured. An innovative trial of the cofactor biotin involving 154 patients with secondary progressive MS was also published [17 & ]. The proposed modes of action include supporting myelin repair and protecting against hypoxiadriven axonal degeneration (by enhancing energy production). The primary end point was unusualthe proportion of patients with disability reversal at month 9 confirmed at month 12. The study was positive and Phase III trials are planned. A Phase III trial of simvastatin in secondary progressive MS will commence later in 2017 -following on from the positive Phase II study [12] . Finally, and most encouragingly, a Phase III trial of Ocrelizumab, a humanized mAb, related to rituximab, that selectively depletes CD-20 expressing B cells, was successful in primary progressive MS [18 && ]. The trial included 732 patients and showed a 24% effect on the primary outcome -12-week confirmed disability progression. Although relatively modest, this effect is a milestone in the therapeutics of progressive MS, reminiscent of the first positive trials of b interferon in relapsing-remitting MS.
Perhaps as encouraging is the focus on neuroprotection for progressive MS. A study by Raftopoulos et al. [19 & ] has demonstrated that neuroprotection may be an important way forward. The study was carried out in an acute model -optic neuritis, applying phenytoin and demonstrated a positive effect. Currently, there are two neuroprotective studies underway, both of which have been fully recruited. The first, SPRINT-MS, a trial of the neuroprotective agent ibudilast involves 155 patients with progressive MS [20] . The primary end point is change in whole brain atrophy as measured by parenchymal brain fraction over 96 weeks. There is also a range of advanced imaging measures. The second study, MS-SMART (Multiple Sclerosis-Secondary Progressive MultiArm Randomisation Trial), has utilized an adaptive trial design to evaluate three neuroprotective agents -amiloride, riluzole, and fluoxetine in secondary progressive MS [21] .
RISK FACTORS, SYMPTOMATIC MANAGEMENT, REHABILITATION, AND COMORBIDITIES
Finally, optimum management of progressive MS includes a range of approaches, beyond potential pharmacological interventions, to modify disease course, including the identification of risk factors which worsen disability, symptomatic management and rehabilitation, and the management of comorbidities. Identifying and quantifying the role of risk factors with potential to modify the evolution of the progressive phase is of paramount importance for patients and clinicians and while many factors are frequently cited as having an impact on disease course, surprisingly few have the necessary evidence base to support this contention. A recent systematic review focused on 14 risk factors and found that there was sufficient evidence to make definitive statements about only three of them; lower vitamin D levels were associated with higher EDSS scores and cigarette smokers had an increased risk of progression, whereas there was no evidence of an association between disease progression and the use of epidural analgesics during childbirth [22 && ]. For the other 11 risk factors, which included diet, alcohol, exercise, and trauma there was insufficient evidence to determine a compelling relationship with progression. In their companion study, 37 trials of the effect of modifiable risk factor interventions on progression were reviewed and no clear beneficial effect from any risk factor was identified [23] . The evidence base for rehabilitation and symptomatic management in progressive MS is also quite limited [24] . However, a recent systematic review of physiotherapy in this population suggested some efficacy though there was a major concern around methodology [25] .
A recently acknowledged area which has a major impact on MS and perhaps particularly on the progressive MS population, is the issue of comorbidities [26] . Two recent studies which emanated from an international workshop clarify the prevalence of key comorbidities in MS [27] and, importantly, determine how they should be incorporated into clinical trials both in terms of safety and efficacy of the intervention under study [28 && ].
CONCLUSION
Activity within the progressive space has increased dramatically and the profile of progressive MS has risen substantially. The blocks to treatment are being actively addressed and we have the first effective agent in primary progressive MS. These advances give cause for optimism but should not be
